At the end of the year, Jiangsu Hengrui Pharmaceuticals has made another achievement in business development, with an ADC new drug receiving a first payment of 75 million USD | Quick read of the announcement.
① This evening, Jiangsu Hengrui Pharmaceuticals announced that the overseas rights for the DLL3 ADC innovative drug SHR-4849 have been granted to USA's IDEAYA Biosciences, resulting in a payment of 75 million USD as an upfront fee; ② Jiangsu Hengrui Pharmaceuticals is accelerating its international development. Previously, Sun Piaoyang stated: going abroad is a path we must take, and how to do it steadily and successfully is a question we continue to explore.
Still not profitable yet involved in multiple patent lawsuits, Yifang Bio claims that it is not involved in the research pipeline.
① Yifang Biotechnology and its controlling person are involved in a patent infringement lawsuit, being asked to pay 99 million yuan. Yifang Biotechnology's revenue for the first three quarters of 2024 is less than 20 million yuan, and it has not yet achieved profitability; ② Company personnel stated that the lawsuit targets some patents related to Yifang Biotechnology's intellectual property and does not involve the research pipeline.
Jiangsu Hengrui Pharmaceuticals plans to list in Hong Kong! The hundred billion yuan pharmaceutical company ranks first among heavyweight in fund stocks in the A-share pharmaceutical sector.
On December 9, Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that, after the approval of the board of directors, in order to further assist the company's international business development, the company plans to issue shares (listed in hong kong) overseas and list on the main board of the Hong Kong Stock Exchange.
Is Guangxi Wuzhou Zhongheng Group planning to sell the controlling stake of Chongqing Lummy Pharmaceutical after years of consecutive losses? | Quick read announcement
①Guangxi Wuzhou Zhongheng Group intends to transfer the shares held directly in Chongqing Lummy Pharmaceutical through public solicitation, and the controlling shareholder and actual controller of the latter may change. ②The story of Guangxi Wuzhou Zhongheng Group's investment in Chongqing Lummy Pharmaceutical began in November 2019 and became a major shareholder of Chongqing Lummy Pharmaceutical in April of the following year, making Guangxi State-owned Assets Supervision and Administration Commission the actual controller of Chongqing Lummy Pharmaceutical since then. ③In recent years, Chongqing Lummy Pharmaceutical has been in a continuous loss-making state.
This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.
Abnormal trading investigation! The big bull stock special treat Jingfeng has been suspended for the first time, with an increase of over 752% in more than four months | Quick read of the announcement.
①*ST Jingfeng suspended trading for the first time this year due to abnormal fluctuations; ② The cumulative deviation of the closing price for two consecutive trading days reached 15.39%; ③ The stock price has increased by 752.78% in the past four months; ④ There is still uncertainty about the highly anticipated pre-restructuring matters.